Gamma Delta T-Cell Therapy: Development of ICT01, A First-In- Class, Anti-BTN3A Antibody For Activating Vγ9Vδ2 T Cell–Mediated Antitumor Immune Response

Time: 12:25 pm
day: Day Two


  • Preclinical models for the development of monoclonal antibody targeting BTN3A, a membrane receptor with no ortholog in mice
  • Biomarker package to support Phase 1 clinical studies with a first-in-class therapeutic activating Vg9Vd2 T cell–mediated antitumor immune response
  •  How biomarkers allow to define the best combination strategies